Close
Help




JOURNAL

Clinical Medicine Insights: Oncology

Paclitaxel as Neoadjuvant Therapy for High Grade Angiosarcoma of the Spleen: a Brief Report and Literature Review

Submit a Paper


Clinical Medicine Insights: Oncology 2010:4107-110

Case Report

Published on 12 Oct 2010

DOI: 10.4137/CMO.S5329


Further metadata provided in PDF



Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Insights: Oncology

Abstract

Introduction: Splenic angiosarcoma is a rare tumor with only a few cases reported in the literature. Surgical resection offers the best chance of cure for this aggressive neoplasm but is often precluded by infiltration of the tumor to surrounding critical structures. We report a case of a locally advanced angiosarcoma rendered operable by treatment with Paclitaxel monotherapy.

Case presentation: A 69 year old female presented with a high grade splenic angiosarcoma, considered inoperable due to the extent of local spread. She received three cycles of single agent Paclitaxel and underwent a successful resection of the tumor.

Conclusion: Chemotherapy options for splenic angiosarcoma are not well studied. Paclitaxel as monotherapy is a useful therapeutic option in down staging tumors, facilitating surgical resection and merits further study in clinical trials.



Downloads

PDF  (1.11 MB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)

XML




What Your Colleagues Say About Clinical Medicine Insights: Oncology
testimonial_image
The team at Libertas Academica stands above the pack as publishers of academic journals.  My recent article in Clinical Medicine Insights: Oncology was handled very professionally throughout the process.  They have my highest regards. 
Dr Jimmy T Efird (East Carolina University, Greenville, NC, USA)
More Testimonials

Quick Links


New article and journal news notification services